SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InterMune (nasdaq)ITMN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: IRWIN JAMES FRANKEL who wrote (331)10/29/2002 12:01:28 AM
From: ewolf  Read Replies (1) of 508
 
I'm not sure you're right. Copegus isn't approved. I thought that approval was supposed to come in December. This november meeting seems to refer to ICN version. Or I may be wrong, though it would be odd to call the drug Ribavirin if it's really copegus. They can't be the same if Roche's claim that they violate no patents is true. The novartis/geneva attempt to establish a generic version has had a recent setback. In any case, a generic version could not be on the market for three years. We'll see soon enough. thanks,eaw
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News